Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Alessandro Carugo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5182-3320; OpenAlex author ID A5050464171. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 2 papers · 2025: none · 2026: 3 papers

Papers 14

  1. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
  2. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. First author DOI 10.1038/s41586-026-10995-6↗
  3. DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-3849↗
  4. WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer Co-author DOI 10.1101/2024.10.21.619543↗
  5. Clonal dominance defines metastatic dissemination in pancreatic cancer. Co-author DOI 10.1126/sciadv.add9342↗
  6. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-021-24798-y↗
  7. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Co-author DOI 10.1158/0008-5472.can-20-3792↗
  8. Diversity Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-Anchored Functional Genomics Co-author DOI 10.1101/2020.09.17.302034↗
  9. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Co-author DOI 10.1038/s41586-019-1062-1↗
  10. Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-0187↗
  11. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. First author DOI 10.1038/nature21064↗
  12. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2016.05.063↗
  13. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-1854↗
  14. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/nature13611↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Timothy Paul Heffernan · 13 shared papers, 2014–2026 · strength 1.31
  2. Giulio Francesco Draetta · 13 shared papers, 2014–2026 · strength 1.27
  3. Andrea Viale · 12 shared papers, 2014–2026 · strength 1.20
  4. Giannicola Genovese · 11 shared papers, 2014–2026 · strength 1.14
  5. Virginia Giuliani · 9 shared papers, 2014–2026 · strength 1.03
  6. Haoqiang Ying · 9 shared papers, 2014–2026 · strength 0.88
  7. Wantong Yao · 9 shared papers, 2014–2026 · strength 0.86
  8. Jason B. Fleming · 10 shared papers, 2014–2026 · strength 0.85
  9. Huamin Wang · 8 shared papers, 2014–2026 · strength 0.77
  10. Anirban Maitra · 7 shared papers, 2016–2026 · strength 0.62
  11. I-Lin Ho · 5 shared papers, 2019–2026 · strength 0.59
  12. Ronald Anthony Depinho · 7 shared papers, 2014–2026 · strength 0.59
  13. Ziheng Chen · 4 shared papers, 2019–2026 · strength 0.51
  14. Francesca Citron · 3 shared papers, 2024–2026 · strength 0.45
  15. Ya’an Kang · 5 shared papers, 2014–2026 · strength 0.44
  16. Piergiorgio Pettazzoni · 6 shared papers, 2014–2026 · strength 0.41
  17. Michael P. Kim · 4 shared papers, 2019–2024 · strength 0.37
  18. Avnish Kapoor · 4 shared papers, 2014–2026 · strength 0.33
  19. Luigi Perelli · 2 shared papers, 2024–2026 · strength 0.31
  20. Johnathon Lynn Rose · 4 shared papers, 2016–2021 · strength 0.26
  21. Lynda Chin · 3 shared papers, 2016–2026 · strength 0.26
  22. Lewis C. Cantley · 2 shared papers, 2014–2026 · strength 0.23
  23. Emanuela Brunetto · 2 shared papers, 2014–2026 · strength 0.23
  24. Alec C. Kimmelman · 2 shared papers, 2014–2026 · strength 0.23
  25. Costas Andreas Lyssiotis · 2 shared papers, 2014–2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.